Holen Sie sich die Stockscreener-App
224.16
0.59%
-1.205
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$225.37
Offen:
$226.89
24-Stunden-Volumen:
1.09M
Relative Volume:
0.17
Marktkapitalisierung:
$396.37B
Einnahmen:
$61.16B
Nettoeinkommen (Verlust:
$4.19B
KGV:
94.93
EPS:
2.3614
Netto-Cashflow:
$17.82B
1W Leistung:
-2.63%
1M Leistung:
-3.22%
6M Leistung:
+2.62%
1J Leistung:
+5.91%
1-Tages-Spanne:
$222.02
$228.62
1-Wochen-Bereich:
$222.02
$231.26
52-Wochen-Spanne:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
224.17 | 398.49B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
LLY
Lilly Eli Co
|
987.64 | 872.68B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
243.44 | 583.29B | 94.19B | 26.80B | 19.70B | 11.05 |
|
AZN
Astrazeneca Plc
|
189.63 | 298.53B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
153.77 | 294.33B | 54.72B | 14.02B | 15.32B | 7.1855 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-04 | Herabstufung | DZ Bank | Buy → Hold |
| 2025-10-14 | Herabstufung | Erste Group | Buy → Hold |
| 2025-10-01 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-08-12 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
AbbVie Inc Stock (ISIN: US00287Y1091) Faces Pressure Amid Valuation Concerns and Dividend Appeal - AD HOC NEWS
AbbVie CEO’s pay jumped 75% to $32.5M in second year at the helm - Crain's Chicago Business
AbbVie Stock: Is This Pharma Giant Still a Buy-or-Bail in 2026? - AD HOC NEWS
The Best Dividend Stocks to Buy and Hold Forever - The Motley Fool
AbbVie Inc. $ABBV Shares Sold by Van ECK Associates Corp - MarketBeat
Douglass Winthrop Advisors LLC Buys 9,022 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Holdings Cut by Bokf Na - MarketBeat
RBC Capital Says AbbVie Inc. (ABBV) Growth Story Is Still in Early Stages - Insider Monkey
Antiviral Drugs Market Is Going to Boom Rapidly| AbbVie Inc., GSK plc, and Dr. Reddy's Laboratories Ltd. - openPR.com
AbbVie Reports Promising Results from Phase 1 Study of ABBV-295 - Yahoo! Finance Canada
How The Narrative For AbbVie (ABBV) Is Shifting On Immunology Growth And Competition Risks - Yahoo Finance
AbbVie’s ABBV-295 Obesity Data Sparks Fresh Interest In Valuation - simplywall.st
UCB's Bimzelx Outperforms AbbVie's Skyrizi in Psoriatic Arthritis Trial - GuruFocus
AbbVie’s Skyrizi beaten by UCB’s Bimzelx in psoriatic arthritis - Seeking Alpha
SageView Advisory Group LLC Buys 13,883 Shares of AbbVie Inc. $ABBV - MarketBeat
Kepler Cheuvreux Suisse SA Takes $7.54 Million Position in AbbVie Inc. $ABBV - MarketBeat
Mackenzie Financial Corp Sells 99,604 Shares of AbbVie Inc. $ABBV - MarketBeat
Scotiabank Reaffirms Their Buy Rating on AbbVie (ABBV) - The Globe and Mail
Franklin Resources Inc. Trims Holdings in AbbVie Inc. $ABBV - MarketBeat
Capital World Investors Sells 139,297 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. (ABBV) gets downgraded to peer perform from outperform by Wolfe Research - MSN
AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial - TechStock²
AbbVie’s GLP-1 challenger posts strong weight-loss results in early trial - Crain's Chicago Business
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Delcath Systems (DCTH) - The Globe and Mail
AbbVie Posts Encouraging Early-Stage Data For Amylin Analog ABBV-295 - Citeline News & Insights
Richard Bernstein Advisors LLC Lowers Holdings in AbbVie Inc. $ABBV - MarketBeat
Capital Research Global Investors Sells 34,749 Shares of AbbVie Inc. $ABBV - MarketBeat
Capital International Investors Has $2.48 Billion Stake in AbbVie Inc. $ABBV - MarketBeat
Capital International Inc. CA Has $55.65 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
Legal & General Group Plc Has $2.78 Billion Holdings in AbbVie Inc. $ABBV - MarketBeat
Bank of Montreal Can Raises Stock Position in AbbVie Inc. $ABBV - MarketBeat
William Blair and BMO Maintain Outperform on AbbVie Inc. (ABBV) March 2026 - Meyka
AbbVie reports ‘positive’ results from Phase 1 study of ABBV-295 - TipRanks
AbbVie says CEO Robert Michael's 2025 total compensation was $32.5 millionSEC filing - marketscreener.com
AbbVie (NYSE:ABBV) Shares Down 1% Following Insider Selling - MarketBeat
ICER to review AbbVie’s Parkinson’s disease drug - The Pharma Letter
AbbVie (ABBV) Reports Promising Phase 1 Results for Obesity Trea - GuruFocus
AbbVie's Early Obesity Drug Data Shows Up To 10% Weight Loss - Benzinga
AbbVie sees promising early-stage data for weight loss asset ABBV-295 - Seeking Alpha
AbbVie Trial Updates Add Context To Valuation And Growth Outlook - Yahoo Finance
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Sienna Gestion Boosts Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie (ABBV) Reports Promising Results from Phase 1 Study of AB - GuruFocus
Gubra's partner AbbVie reports positive phase 1 results for ABBV-295 - marketscreener.com
AbbVie reports Positive Phase 1 Multiple Ascending Dose Results for ABBV-295, a Long-Acting Amylin Analog - TradingView
AbbVie Inc. $ABBV Shares Purchased by Schroder Investment Management Group - MarketBeat
Swiss National Bank Trims Stake in AbbVie Inc. $ABBV - MarketBeat
AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults - Yahoo Finance
AbbVie Inc. $ABBV Shares Acquired by LGT Group Foundation - MarketBeat
Russell Investments Group Ltd. Increases Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Jefferies Financial Group Inc. Sells 53,123 Shares of AbbVie Inc. $ABBV - MarketBeat
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.31%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):